
News|Videos|December 15, 2020
Collecting Real-World Data from Patients With Myelofibrosis Is Essential
Rami Komrokji, MD, discusses whether the majority of patients in the MOST study were being treated at the time of enrollment, and why real-world data is so essential.
Advertisement
In an interview with Pharmacy Times, Rami Komrokji, MD, clinical director of malignant hematology and department lead clinical investigator at the H. Lee Moffitt Cancer Center and Research Institute, spoke about the importance of real-world data in patients with myelofibrosis. Komrokji presented at the 62nd American Society of Hematology Annual Meeting and Exposition on ‘To Treat or Not to Treat? Understanding Treatment Patterns in Patients with Lower-Risk Myelofibrosis at the Time of Enrollment in the MOST Study.’
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
3
Real-World Use of Talazoparib Plus Enzalutamide and HR Testing Trends in Prostate Cancer
4
Alzheimer Updates, Stroke Breakthroughs, and the Case for Early Treatment
5




























































































































